Overview
Cristcot develops therapies for gastrointestinal diseases, starting with Sephure, a patented, FDA-cleared disposable rectal-suppository applicator that enables hygienic, comfortable, and rapid administration. The device is sold globally to consumers and can be used with various suppositories, improving placement and reducing leakage by letting air escape during insertion and withdrawal. Building on the device platform, Cristcot advances drug-device combinations, led by a hydrocortisone acetate 90 mg suppository for ulcerative colitis that has completed Phase 3 trials. The company pursues 505(b)(2) formulations to target unmet GI needs and plans to commercialize its products, with a pipeline including ulcerative colitis, acute pancreatitis, and hemorrhoid disease.
Work here?Claim your company
Simplify's take
What believers are saying
- FDA accepted ngHCA's NDA on April 21, 2026, validating the Phase 3 package.
- Rayna Herman joined May 6, 2026, accelerating commercial launch preparation before approval.
- Phase 3 CESSA showed 21.2% remission versus 1.5% placebo, supporting label strength.
What critics are saying
- WuXi Clinical Development's Delaware contract lawsuit clouds manufacturing reliability and partner trust in 2026.
- Cristcot depends on ngHCA; a negative FDA decision strands its only near-term revenue.
- If ngHCA fails, 2027 financing collapses and Cristcot becomes a device-only niche seller.
What makes Cristcot unique
- Sephure makes rectal suppositories easier, cleaner, and more accurate than manual insertion.
- ngHCA pairs a patented applicator with 505(b)(2) hydrocortisone acetate for ulcerative colitis.
- Cristcot targets overlooked gastrointestinal delivery problems, not crowded systemic gastroenterology markets.
Help us improve and share your feedback! Did you find this helpful?